Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Kura Oncology (KURA) will report Q1 2026 results before the market opens on Thursday, May 7; analysts expect EPS of ($0.8099) and $25.77 million in revenue, with a conference call scheduled for 4:30 PM ET.
• The company missed prior-quarter expectations (reported ($0.92) EPS vs. consensus ($0.72) and $17.34M revenue vs. $34.71M est.), showing a deeply negative net margin and ROE, and analysts forecast roughly ($3) EPS for the current fiscal year and ($2) next year.
• KURA trades around $8.75 with a 12‑month range of $5.45–$12.49 and a market cap of about $776.7M; Wall Street’s average rating is a Moderate Buy with an average price target of $26.38, and several large institutions (State Street, Renaissance, AQR) have recently increased holdings.

Kura Oncology (NASDAQ:KURA - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.8099) per share and revenue of $25.7680 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.20). The business had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million. Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. On average, analysts expect Kura Oncology to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kura Oncology Stock Performance

KURA stock opened at $8.75 on Thursday. Kura Oncology has a 12-month low of $5.45 and a 12-month high of $12.49. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average of $8.72 and a 200-day moving average of $9.49. The firm has a market cap of $776.68 million, a PE ratio of -2.75 and a beta of 0.25.

Wall Street Analyst Weigh In

KURA has been the topic of several research analyst reports. Lake Street Capital initiated coverage on Kura Oncology in a research note on Tuesday, April 14th. They issued a "buy" rating and a $23.00 price objective on the stock. Mizuho dropped their price objective on Kura Oncology from $30.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 24th. Wedbush dropped their price objective on Kura Oncology from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, March 6th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Tuesday, January 13th. Finally, Leerink Partners set a $20.00 price objective on Kura Oncology and gave the company an "outperform" rating in a research note on Tuesday, January 13th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $26.38.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently made changes to their positions in KURA. State Street Corp lifted its position in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company's stock worth $51,234,000 after acquiring an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company's stock worth $19,688,000 after acquiring an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company's stock worth $19,020,000 after acquiring an additional 965,256 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company's stock worth $31,816,000 after acquiring an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in shares of Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company's stock worth $11,032,000 after acquiring an additional 738,761 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.